Towa Pharma International Holdings Revenue and Competitors

We are the international subsidiary for the Japanese company Towa Pharmaceutical in Europe and the United States. We share its purpose, to contribute to people’s overall health and wellbeing by improving and extending life expectancy. 👉 We have more than 20 years’ experience 👈 developing, manufacturing and marketing added-value generic drugs designed and devised to improve the lives of patients and healthcare professionals. With our work, we seek to contribute to the sustainability of public healthcare systems 🌍 , to the access to drugs and to creating a healthy environment for the future generations. Our moment 🔥 High-quality, added-value and affordable generic drugs are our area of expertise. The headquarters of Towa International are in Martorelles (Barcelona), where we develop and manufacture most of our products. We are recognised as experts in modified-release products and have one of Europe’s largest production plants devoted to this technology. We were the first company in the world to develop and market the first generic version of Omeprazol, and we complement our product portfolio through strategic partnerships with third parties. We market our products under our own brands (Breckendrige, Pensa and ToLife) through our own sales networks across the United States, Spain, Italy, Portugal, Sweden and Germany. Additionally, our products are available almost everywhere in the world through marketing licenses granted to third parties by our Business to Business division. Our goal is to build long-term relationships with our clients 🎯 : Other companies from the sector, distributors, public healthcare systems or pharmacies. We work to bring genuine smiles onto the faces of our patients. The quality and excellence of our products are the signature features of Towa Pharmaceutical, which we aim to export around the world. Non-Financial Report 2020: https://bit.ly/3tVJ5Ca